Full-Time

Genmed

Posted on 12/10/2024

Sanofi

Sanofi

10,001+ employees

Develops pharmaceuticals and life-saving vaccines

Biotechnology
Healthcare

Senior, Expert

Reading, UK

Category
Physicians & Surgeons
Medical, Clinical & Veterinary
Requirements
  • Strong track record in developing and executing medical strategy in UK and Ireland and leading a sizable medical affairs function
  • Strong compliance background as a UK PMCPA Level 4 signatory or ability to train as UK PMCPA Level 4 signatory
  • Demonstrated track record of building and maintaining a strong KOL (Key Opinion Leader) network in UK/IR.
  • Experience in working across and building effective partnerships among R&D, Commercial, Medical, Market Access, Public Affairs, Safety, and Regulatory
  • Strategic and innovative thinking; comfortable with making bold decisions; ease to move from activity to impact.
  • Transformative leadership: Ability to create and articulate a vision for the medical organization and embark teams in that evolutive journey.
  • High energy, motivated, driven, with the ability to think and contribute beyond functional expertise.
  • Influential leadership: ability to positively influence peers, senior leaders, key external stakeholders, and internal partners.
  • Education: scientific background: i.e. Medical Degree, PhD, PharmD (MD preferred).
  • Oral and written fluency in English
Responsibilities
  • Drive the medical strategy and activities for prelaunch, launch and post-launch of GEM GBU products; ensure optimal life cycle management for all products in partnership with all relevant functional counterparts
  • Build scientific ecosystem in UK/IR embracing transformative therapies in aT1D and Transplant areas leveraging partnerships with relevant scientific and institutional stakeholders (key opinion leaders, external experts, health technology assessment bodies and health regulatory authorities). Maintain and reinforce the strategic & scientific position of Sanofi in the UK/IR healthcare ecosystem
  • Provide strategic leadership for the medical function in UK/IR and partner with the business to co-create the coherent strategic action plan, ensuring scientific rigor and patient outcomes
  • Ensure all necessary conditions are met in terms of medical strategy, planning and resourcing for successful launch of transformative therapies in autoimmune T1D and Transplant areas
  • Develop a compelling vision for Medical Affairs in UK/IR in accordance with company ‘GLocal model’ principles, aligned with global medical strategy and business objectives.
  • Lead optimization and execution of affiliate medical plans that maximize product value. Proactively enable and drive cross-functional partnerships across medical and non-medical functions – commercial, market access, public affairs, regulatory, safety, clinical operations, R&D – to ensure building of integrated plans - including data generation - across all functions, (reports, publications, presentations to health authorities, presentations to scientific congresses, or company sponsored events)
  • Lead the DRIVE transformation and develop high performing teams & talent pipeline. Develop agile ways of working within the UK/IR Sanofi organization, with a ‘customer first’ mindset, foster strong collaboration with a global Go To Market Capabilities organization
  • Manage responsibly and proactively the country medical budget. Identify synergies, propose the appropriate resource allocation for medical initiatives at General Medicines and cross-GBU level
  • Leverage Real World data and deploy Artificial Intelligence and digital enablers to generate evidence and insights, to improve medical affairs decisions and operational efficiency, aiming to improve patient outcomes

Sanofi provides healthcare solutions through its pharmaceutical and biotechnology products, focusing on treatments and vaccines for various medical conditions. The company conducts extensive research and development to create new therapies and improve existing ones, particularly in areas like immunology, oncology, and rare diseases. Sanofi's products include prescription medicines, over-the-counter items, and vaccines, which are distributed to patients, healthcare professionals, and governments. What sets Sanofi apart from its competitors is its strong emphasis on scientific innovation and strategic partnerships, allowing it to maintain a diverse pipeline of new products. The company's goal is to enhance health outcomes and improve the quality of life for people globally by delivering effective and safe healthcare solutions.

Company Stage

IPO

Total Funding

$2B

Headquarters

Paris, France

Founded

1973

Growth & Insights
Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Simplify Jobs

Simplify's Take

What believers are saying

  • AI-driven Muse tool can reduce clinical trial timelines and costs.
  • Dupixent's potential approval for chronic urticaria could expand Sanofi's market share.
  • Investment in SureChill aligns with sustainability trends and improves vaccine distribution.

What critics are saying

  • Muse's adoption may face privacy concerns and regulatory scrutiny.
  • ZT-01 trial may not yield expected returns for Sanofi's diabetes investment.
  • Dupixent's FDA review delays could impact market position in chronic urticaria.

What makes Sanofi unique

  • Sanofi's collaboration with OpenAI on Muse enhances patient recruitment in clinical trials.
  • Dupixent's approval for eosinophilic esophagitis in children opens new pediatric markets.
  • Investment in Orano Med positions Sanofi in innovative radioligand cancer therapies.

Help us improve and share your feedback! Did you find this helpful?